BY HEATHER SMITH THOMAS

Research trials are assessing a new process for treating multidrug-resistant bacterial joint infections (septic arthritis) in foals. This research is a partnership between Colorado State University, Ontario Veterinary College in Guelph and Rood and Riddle Equine Hospital in Kentucky.

Dr. Thomas Koch (Department of Biomedical Sciences, Ontario Veterinary College), founder and CEO of eQcell—a company partnering in this research, has co-authored several papers looking at combining antibiotics and stem cells in treating these resistant infections. Mesenchymal stromal cells (MSCs) were used in conjunction with antibiotics, with good results.

Antimicrobial resistance (AMR) has been a growing concern in treating humans as well as animals. Emergence of “superbugs” resistant to antimicrobial medications threatens animal and human populations due to widespread use of antibiotics. In recent years, the American Veterinary Medical Association (AVMA), the Federation of Veterinarians of Europe (FVE) and the Canadian Veterinary Medical Association (CVMA) released a joint statement on responsible and judicious use of antimicrobials and published guidelines for appropriate veterinary antimicrobial use. Many federal agencies in various countries are moving to reduce the use of antimicrobials in animals.

A different approach must be sought to find alternatives to or enhancements of conventional antimicrobials. Clinicians today may want to consider other strategies for treating microbial infections, and one strategy may include mesenchymal stromal cells (MSCs). These unique cells have been explored in regenerative medicine, for engineering tissues or as immune-stimulating agents for treatment of inflammatory diseases. More recently, MSCs have shown promise as a potential treatment to address infections that are resistant to antimicrobial treatments, Koch points out.

“MSCs have antimicrobial properties; they secrete antimicrobial molecules (peptides) that directly interact with pathogens, as well as other factors (cytokines) that boost antimicrobial activity of the host’s own immune cells. In some studies, MSCs have shown strong synergy with standard antibiotic treatments to penetrate biofilm infections, as well as serving as antifungal, antiviral and anti-parasitic agents,” he says.

MSCs have antimicrobial properties that may help solve the problem of antibiotic-resistant bacteria. “Recent findings in equine, canine and bovine studies have shown that MSCs have significant effects on a variety of bacterial species either alone or in combination with antibiotics,” says Koch.

MSCs exert their effect directly through secretion of various bioactive factors or indirectly through recruitment and activation of host immune cells. MSCs may become a valuable tool for veterinarians treating antimicrobial resistant infections, but a great deal of work remains for the development of optimal MSC production conditions, and testing for efficacy on different indications and species.

“The studies at Colorado State University have been going on awhile; I came into this project to collaborate with them—but initial groundwork was done by Drs. Steven Dow and Lynn Pezzanite at CSU,” Koch says. Now his company, eQcell, has joined with them to push their discovery toward commercialization.

EARLY STUDIES WITH MICE - “They did some interesting work in dogs and horses but started out with mice. They made skin wounds in mice and infected the wounds with multi-drug resistant bacteria. Then they treated the mice in different ways.”

Some mice were left untreated, and some were treated with antibiotics alone or stem cells alone. Another group was treated with manipulated stem cells, activated in culture to be more antibacterial. “Then they treated some of the mice with combinations of either stem cells and antibiotics, or activated stem cells and antibiotics,” Koch says.

“They saw the best response (clearing up infections) in the mice that received the antibiotic plus the manipulated stem cells. With this combination there was a synergistic effect with the MSCs, compared with antibiotic alone,” he says.

The stem cells alone were not good enough and the antibiotic alone was not as effective. They determined that the manipulated MSCs could be utilized as an add-on treatment with antibiotics to improve infection control. “You still need to treat with antibiotics but if you add stem cells there is a better response than with antibiotics alone. It is not completely clear what the underlying mechanism is but there is a synergistic effect with the combination.”

RESEARCH IN DOGS - Then the researchers treated seven dogs at the CSU teaching hospital. “These were client-owned dogs with documented bacterial infections and multi-drug resistance. They were not responding to the prescribed antibiotic treatments even though the veterinarians were using very potent antibiotics,” says Koch. The infections varied in duration from several months to almost two years. “They had different types of conditions; the infections were quite varied, but they were all deep-seated and long-lasting in spite of treatment,” he explains. “They treated these dogs three times, two weeks apart, with intravenous infusion of manipulated stem cells. In five of the seven dogs they saw a complete cure; the infection cleared up and the dogs became healthy, without any signs. Bacterial testing and culture sensitivity showed that the infection was no longer there.” The other two dogs were partial responders. There was some improvement, but not a complete cure. Dr. Steven Dow, Professor at Colorado State University and Director of the Center for Immune and Regenerative Therapies, has now treated many dogs successfully at the vet school using this combination therapy. “These were dogs with chronic drug-resistant infections. We know that it works in larger animals and not just mice. We have a good level of understanding about this therapy and a good level of comfort using this to treat dogs,” Dow says.

The dogs in his study were people’s pets, with a variety of infections that had not responded to treatment for at least a month. Some were joint infections, some were soft tissue and some were bone infections. The results were exciting.

RESEARCH WITH HORSES – “A study with horses was funded by the Grayson Jockey Club, using research horses,” says Koch. Normal joints were infected with a USA300 MRSA superbug bacterium that had been isolated from a human patient and donated to the research group. Those joints became infected, and the horses become lame.

“They treated some of these infected joints with antibiotic alone—one that they would normally choose, and expected to work

Dr. Steven Dow Dr. Lynn Pezzanite Equine Care continues on next page

against those bacteria based on culture and sensitivity. A second group was treated with the same antibiotic plus manipulated stem cells. They saw a significant improvement in joints treated with manipulated MSC and antibiotics in degree of lameness and other outcome parameters including reduced bacterial burden and inflammatory cytokine levels. Overall, there was a significant effect when adding the manipulated stem cells to the treatment protocol,” Koch says.

Horses that got the combination cleared the infection and were less lame and had a better treatment response. This preliminary effort paved the way to move into treating client-owned horses, to try to assess whether adding stem cells to antibiotics will have an effect in those horses with naturally-occurring (rather than induced) bacterial infections in joints.

Dr. Lynn Pezzanite (Assistant Professor, Colorado State University College of Veterinary Medicine) began her PhD project in Dr. Dow’s lab. “Some of the initial groundwork with in-vitro human MSCs and initial mouse studies were already ongoing in Dow’s lab when I began my graduate program,” Lynn says.

“Part of my thesis was funded by an NIH program in partnership with the UC Denver medical school, with the goal of encouraging communication between the veterinary and medical school programs. One of Dr. Dow’s collaborators, Jason Stoneback, Chief of Orthopedic Surgery and Director of the Limb Restoration Program at the medical school was my mentor through the program. He works with challenging human orthopedic cases, which present many of the same difficulties in treatment; they are often complicated by infection with multidrug resistant bacteria. He was interested in this kind of treatment for humans as well. Use of our anti-infective cellular therapies in larger animal models, dogs and horses, provides further support for integration of these therapies in human clinical trials,” she says.

“Treating horses with infection is my main focus here at the veterinary school but our findings also represent a translational model for humans suffering from the same processes.” She has submitted a paper for publication describing the work she’s done using an equine model, looking at septic arthritis in adult horses.

“In adult horses we’ve seen more rapid improvement, both in clinical parameters and lameness and in their overall pain/inflammation scores—in the horses treated with stem cells and antibiotics

versus just antibiotics alone,” she says. “Some of our in vitro outcomes were also exciting in terms of how these cells work. There is certainly more to learn in terms of how these cells are exerting their effects but our study findings in adult horses with joint infections demonstrated that those treated with stem cells had lower levels of inflammatory cytokines and more rapid healing/ normalization of joint fluid parameters, including white cell count and inflammatory mediator serum amyloid A. They also had lower bacterial bioburden in their joints based on quantitative cultures compared to horses that received antibiotics alone,” she says. NEW STUDY WITH FOALS - Dr. Scott Hopper at Rood and Riddle Equine Hospital in Kentucky is a part of the study in foals. “Their practice frequently treats Thoroughbred foals intended to be racehorses. Foals often encounter a number of systemic diseases in their early months of life. These include colitis, umbilical and respiratory issues and all of these can get into the bloodstream and seed infections into the joints. They are very susceptible to joint infections,” Lynn says. “This study will employ the same techniques that Dr. Dow pioneered in the lab and what we did in adult horses, using activated stem cells in combination with antibiotics in the joint itself.” Foals in the study will be randomized into groups. Some will Stem cell culture by Dr. Pezzanite receive the standard treatment of lavaging and debriding the joint and others will receive standard treatments and this new treatment of stem cells. Joint infections, especially those that don’t respond to standard treatments, can leave the joint permanently damaged. If they develop arthritis secondary to infection and become lame, the horse won’t have an athletic career. This new treatment will be an exciting improvement if it works for these foals, not only to hopefully improve treatment of the infection initially but potentially improve long-term athletic outcomes. “A large part of our interest and enthusiasm for using this in foals is knowing that it works in dogs—which are more the size of a foal than the earlier mouse models,” says Dow. “We can probably use doses equivalent to what we’ve been using in dogs. We also know that infusions of these activated stem cells are very safe.” The researchers chose to start their new study with foals less than 6 months of age. “These are foals that have been diagnosed with joint infections which may be due to infections in other areas

of the body, such as the intestine or umbilicus,” Koch explains.

Some foals have more than one joint infected—if bacteria have spread through the bloodstream. A foal may have bacterial invasion that enters via the navel stump, lungs or digestive tract, getting into the bloodstream to cause a bacteremia or septicemia and that’s how it gets seeded into the joints—affecting more than one joint. “If it’s a foal with multiple joints affected, all those joints will get the stem cells if that foal is allocated to the stem cell treatment group,” he explains.

“We have selected four different antibiotics--chosen by researchers in Colorado after evaluating a number of antibiotics to find out which ones the stem cells can tolerate. Some antibiotics are toxic to them and will kill stem cells. They screened a number of antibiotics to determine their degree of cell toxicity. We’re using four antibiotics that should not affect the cells too badly,” he says.

“We have a hierarchy of treatment for this study. First we’ll use a certain antibiotic and if that fails to make a difference we can go to another antibiotic and so on. There will be foals that only receive antibiotics and they will be our control group. Then there will be foals that receive that same antibiotic plus stem cells.”

This study is being conducted at three locations. “Foals that come to Colorado State University with joint infections will be treated at their teaching hospital. Foals will also be treated at the Ontario Veterinary College Teaching Hospital and at Rood and Riddle Equine Hospital in Kentucky. We expect the majority of foals will be enrolled at Rood and Riddle because the teaching hospitals don’t see as many foals. We grow cells in the lab and ship them to Rood and Riddle. Dr. Hopper at Rood and Riddle is the equine surgeon putting together the protocol; some of his colleagues at that hospital will also be treating foals,” says Koch.

It’s hoped that this new treatment will accelerate healing of joint infections in foals. “The cell treatment given in conjunction with antibiotics won’t replace the antibiotic; they work together,” says Dow. “If the foal study gives positive results, we will deliver the cells intravenously, rather than just injected into the joint. We showed in the mouse and dog studies that cells given intravenously can find their way through the body to sites of inflammation or infections. Giving cells intravenously is a lot easier to do than to inject them into the joint,” Dow says.

This new treatment will be a way to deal with drug-resistant infections and also help clear the joint infection before the cartilage is damaged. Then the foals have a better chance to return to full function and a chance to grow up to be athletes. TFH

Dr. Fager, Affirmed & In Reality winner Awesome Strong, by Awesome Slew out of Pleasant Ring, by Pleasant Tap Breeder: John B. Penn Owner: CSLR Racing Partners

2-Year-Old Payment* $250 by Jan. 15

Late 2-Year-Old Payment* $500 by Feb. 28

Yearling Payment $250 by May 15

Late Yearling Payment $500 by Nov. 15

After Nov. 15 – $5,000 by Jan. 15

Last chance payment option of $10,000 by May 1 of 2-year-old year (horse must not have started) For forms or details visit www.ftboa.com

* All terms of FSS races and FTBOA purse supplements, including number of races, purse levels, race conditions, racing dates and the host track may change from year to year and may change at any point after the FSS racing schedule for a particular year is announced. 46867

FLORIDA DEPARTMENT OF AGRICULTURE ............................................................................12-13, 18-19 FLORIDA THOROUGHBRED BREEDERS’ AND OWNERS’ ASSOCIATION ..................................5, 9, 11, 39, 43 OCALA BREEDERS’ SALES COMPANY..................................................................................................... 2 OCALA STUD ...................................................................................................................... BACK COVER PETERSON SMITH EQUINE HOSPITAL + COMPLETE CARE...................................................................... 31 STONEHEDGE FARM SOUTH.................................................................................................................. 3

• Lonny Powell – CEO, Executive Vice

President – FEC CEO & Publisher • Brock Sheridan – Editor-in-Chief • Tammy Gantt – Associate Vice President -

Membership Services & Events – FEC Contributing Editor - Industry & Community Affairs

• Rick Heatter

• Michael Costanzo – Racing Secretary • Peter Aiello IV – Track Announcer

• James Pelrine – Vice President, Business Operations

• Tom Ventura – President • Kevin Honig – Mutuels

• Allison DeLuca – Racing Secretary

• Todd Pletcher • Chuck Simon • Matthew O’Connor

• Michael Weiss